Category: Federal Forum Posters
Purpose: Opioid use disorder is a condition that causes significant morbidity and mortality, in addition to added healthcare costs and societal burdens. Medication assisted treatment is an option to assist patients with recovery and abstinence. There is little data that investigates the gender differences with prescription opioid use and medication assisted treatments. The primary objective of this study is to assess the use and outcomes of medication assisted treatment in men and women who have a history of opioid use disorder.
Methods: This study will be a retrospective electronic chart review of patients with opioid use disorder who were treated with methadone, buprenorphine, naltrexone, or a combination of agents. Patients who received medication assisted treatment from August 1, 2017 to July 31, 2018 will be obtained to generate a patient list. Patients will be included if they have a diagnosis of opioid use disorder (using ICD-9/ICD-10 codes) and are treated in the Substance Use Disorder Recovery Program (SUDRP) clinic. Patients will be excluded if they use methadone, buprenorphine, or naltrexone for indications other than opioid use disorder, or receive these medications from an outside provider. A list of females will be generated, then an equal number of men will be randomly selected based on age. The primary outcomes of the study are to assess medication assisted treatment prescribed for opioid use disorder, the incidence of relapse, and the method of patient referral to SUDRP. Secondary outcomes include documented opioid use and morphine equivalent dose prior to medication assisted treatment, reported relapse, reported compliance with medication assisted treatment, comorbid disease states, childbearing potential, highest dose of medication assisted treatment medication, and medication possession ratio.
Results: not applicable
Conclusion: not applicable
Claire Mattison– PGY1 Pharmacy Practice Resident, Richard L. Roudebush VA Medical Center, Zionsville, IN